anti-mCD3-MDNA132
/ Medicenna
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 17, 2023
Medicenna Presents Preclinical IL-13 Superkine Data at the AACR Annual Meeting
(GlobeNewswire)
- "Anti-mCD3-MDNA132: In vitro data demonstrate the molecule retains strong binding affinity to both IL-13Rα2, expressed on tumors, and CD3, expressed by cancer fighting immune cells. The ICE™ platform is designed to overcome cancer cells’ immune escape by recruiting the patients’ own immune cells to directly target immunologically 'cold' tumors."
Preclinical • Oncology
1 to 1
Of
1
Go to page
1